

# CITATION REPORT

List of articles citing

## Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike

DOI: 10.1016/j.xcrm.2020.100126  
Cell Reports Medicine, 2020, 1, 100126.

**Source:** <https://exaly.com/paper-pdf/75478020/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
176	Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals. <i>MBio</i> , <b>2020</b> , 11,	7.8	118
175	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. <b>2020</b> , 183, 1024-1042.e21		601
174	Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins. <i>Viruses</i> , <b>2020</b> , 12,	6.2	17
173	Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles. <i>Cell Host and Microbe</i> , <b>2020</b> , 28, 880-891.e8	23.4	70
172	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. <b>2020</b> , 5, 1598-1607		667
171	Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity. <b>2020</b> , 5,		28
170	Humoral Responses and Serological Assays in SARS-CoV-2 Infections. <b>2020</b> , 11, 610688		90
169	Serological Surveillance of COVID-19 Hospitalized Patients in Réunion Island (France) Revealed that Specific Immunoglobulin G Are Rapidly Vanishing in Severe Cases. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	1
168	Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization. <i>Viruses</i> , <b>2020</b> , 12,	6.2	19
167	Multicenter Evaluation of the Clinical Performance and the Neutralizing Antibody Activity Prediction Properties of 10 High-Throughput Serological Assays Used in Clinical Laboratories. <b>2021</b> , 59,		15
166	Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <b>2021</b> , 223, 56-61		42
165	Decline in neutralising antibody responses, but sustained T-cell immunity, in COVID-19 patients at 7 months post-infection. <b>2021</b> , 10, e1319		13
164	A distinct innate immune signature marks progression from mild to severe COVID-19. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 100166	18	48
163	SARS-CoV-2 and approaches for a testing and diagnostic strategy. <b>2021</b> , 9, 8157-8173		1
162	Cross-validation of ELISA and a portable surface plasmon resonance instrument for IgG antibody serology with SARS-CoV-2 positive individuals. <b>2021</b> , 146, 4905-4917		7
161	Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19). <b>2021</b> , 11, 89		15
160	A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. <b>2021</b> , 12, 542		86

159	Single-Molecule FRET Imaging of Virus Spike-Host Interactions. <i>Viruses</i> , <b>2021</b> , 13,	6.2	5
158	High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples. <b>2021</b> , 61, 1377-1382		13
157	In silico analysis suggests less effective MHC-II presentation of SARS-CoV-2 RBM peptides: Implication for neutralizing antibody responses. <i>PLoS ONE</i> , <b>2021</b> , 16, e0246731	3.7	3
156	COVID-19: Rethinking the Lockdown Groupthink. <b>2021</b> , 9, 625778		29
155	Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike. <b>2021</b> ,		13
154	Localized and Systemic Immune Responses against SARS-CoV-2 Following Mucosal Immunization. <b>2021</b> , 9,		11
153	SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients. <b>2021</b> , 12, 629185		11
152	SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals. <i>Scientific Reports</i> , <b>2021</b> , 11, 5934	4.9	13
151	Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 Long Term Care Facilities (VIVALDI study).		3
150	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality.		5
149	Live Imaging of SARS-CoV-2 Infection in Mice Reveals Neutralizing Antibodies Require Fc Function for Optimal Efficacy. <b>2021</b> ,		10
148	SARS-CoV-2 - SYNOPTIC CHART OF THE MAIN CHARACTERISTICS OF VIRUS, PATHOGENESIS, IMMUNE RESPONSE, IMMUNOPROPHYLAXIS. <b>2021</b> , 80, 51-80		0
147	Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2. <i>Cell Reports</i> , <b>2021</b> , 34, 108790	10.6	48
146	Bovine Coronavirus Immune Milk Against COVID-19. <b>2021</b> , 12, 637152		5
145	Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. <b>2021</b> , 9,		34
144	Identification of SARS-CoV-2-specific immune alterations in acutely ill patients. <b>2021</b> , 131,		6
143	Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects. <i>Viruses</i> , <b>2021</b> , 13,	6.2	14
142	Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents. <b>2021</b> ,		3

141	Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 100253	18	18
140	Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab220	1	15
139	Longitudinal detection of SARS-CoV-2-specific antibody responses with different serological methods.		1
138	Short-term antibody response and tolerability after one dose of BNT162b2 vaccine in patients receiving hemodialysis: A report from the Quebec Renal Network COVID-19 study.		
137	Systems serology detects functionally distinct coronavirus antibody features in children and elderly. <b>2021</b> , 12, 2037		42
136	Long-term persistence of RBD memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 100228	18	34
135	A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics. <b>2021</b> , 224, 218-228		10
134	Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing. <b>2021</b> , 7, e06836		3
133	International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Protocols, Challenges and Lessons Learned: Summary. <b>2021</b> , 116, 1117-1135		0
132	Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. <b>2021</b> , 12, 2938		110
131	ABO blood group is involved in the quality of the specific immune response.		1
130	Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 100290	18	68
129	Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis. <b>2021</b> , 193, E793-E800		22
128	SARS-CoV-2 seroprevalence among blood donors in Québec, and analysis of symptoms associated with seropositivity: a nested case-control study. <i>Canadian Journal of Public Health</i> , <b>2021</b> , 112, 576-586	3.2	10
127	Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 100275	18	24
126	Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. <i>Cell Reports</i> , <b>2021</b> , 35, 109109	10.6	7
125	International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Responses. <b>2021</b> , 116, e71-e120		1
124	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <b>2021</b> , 9,		2

123	Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients. <i>IScience</i> , <b>2021</b> , 24, 102489	6.1	3
122	Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses. <b>2021</b> ,		21
121	Advances in Neutralization Assays for SARS-CoV-2. <b>2021</b> , 94, e13088		10
120	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. <b>2021</b> , 54, 1276-1289.e6		60
119	Longitudinal detection of SARS-CoV-2-specific antibody responses with different serological methods. <b>2021</b> , 93, 5816-5824		6
118	SARS-CoV-2 infection in fully vaccinated healthcare workers. <b>2021</b> , 114, 183-184		2
117	Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. <i>Cell Host and Microbe</i> , <b>2021</b> , 29, 917-929.e4	23.4	55
116	Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study. <b>2021</b> , 2, e362-e370		32
115	The serological diversity of serum IgG/IgA/IgM against the SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan.		2
114	Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients. <b>2021</b> , 9,		11
113	Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing. <b>2021</b> , 6, 13		1
112	A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. <i>Cell Host and Microbe</i> , <b>2021</b> , 29, 1137-1150.e6	23.4	68
111	Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2.		2
110	Impact of temperature on the affinity of SARS-CoV-2 Spike for ACE2. <b>2021</b> ,		3
109	Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2. <i>Viruses</i> , <b>2021</b> , 13,	6.2	24
108	Performance comparison of micro-neutralization assays based on surrogate SARS-CoV-2 and WT SARS-CoV-2 in assessing virus-neutralizing capacity of anti-SARS-CoV-2 antibodies. <b>2021</b> , 3, 000257		1
107	Duration of SARS-CoV-2 sero-positivity in a large longitudinal sero-surveillance cohort: the COVID-19 Community Research Partnership. <b>2021</b> , 21, 889		8
106	Contribution of single mutations to selected SARS-CoV-2 emerging variants Spike antigenicity.		3

105	Diagnostic Properties of Three SARS-CoV-2 Antibody Tests. <b>2021</b> , 11,	2
104	Covid-19 vaccine immunogenicity in people living with HIV-1.	5
103	Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand. <i>PLoS ONE</i> , <b>2021</b> , 16, e0255796	3.7 0
102	Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern. <b>2021</b> ,	5
101	Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity. <b>2022</b> , 94, 388-392	16
100	The prevalence of adaptive immunity to COVID-19 and reinfection after recovery <a href="#">[a]</a> comprehensive systematic review and meta-analysis of 12 011 447 individuals.	1
99	Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. <b>2021</b> , 9,	5
98	Seroprevalence of anti-SARS-CoV-2 IgG and IgA antibodies before the launch of COVID-19 vaccination in Kazakhstan.	0
97	Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. <b>2021</b> , 54, 2143-2158.e15	37
96	Neglected roles of IgG Fc-binding protein secreted from airway mucin-producing cells in protecting against SARS-CoV-2 infection. <b>2021</b> , 27, 423-436	1
95	Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a sixteen-week interval between doses.	4
94	An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 mice.	4
93	Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents. <b>2021</b> , 6,	15
92	Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2. <b>2021</b> , 297, 101151	12
91	Evaluation of commercial SARS-CoV-2 serological assays in Canadian public health laboratories. <b>2021</b> , 101, 115412	2
90	Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity. <b>2021</b> , 563, 134-145	25
89	Evaluation of a Commercial Culture-free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an Anti-RBD ELISA Assay.	3
88	Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2.	3

87	Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand. <b>2021</b> , 10, e1261		15
86	Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?. <b>2020</b> , 63, 1833-1849		13
85	Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2. <b>2021</b> , 223, 957-970		30
84	Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. <b>2020</b> ,		30
83	Characteristics of anti-SARS-CoV-2 antibodies in recovered COVID-19 subjects.		3
82	Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2.		9
81	Sex differences in the decline of neutralizing antibodies to SARS-CoV-2.		12
80	Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand.		3
79	Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset. <b>2020</b> , 136, 2588-2591		78
78	Long-term kinetics of anti-SARS-CoV-2 antibodies in a cohort of 197 hospitalized and non-hospitalized COVID-19 patients. <b>2021</b> , 59, e179-e183		7
77	Lactoferrin as Antiviral Treatment in COVID-19 Management: Preliminary Evidence. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	10
76	Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel. <i>Seminars in Immunology</i> , <b>2021</b> , 55, 101507	10.7	5
75	Prevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 2020. <i>Wiener Klinische Wochenschrift</i> , <b>2021</b> , 133, 1272	2.3	3
74	Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. <i>Cell Discovery</i> , <b>2021</b> , 7, 96	22.3	5
73	SARS-CoV-2 variants exhibit increased kinetic stability of open spike conformations as an evolutionary strategy.		1
72	MHC-II constrains the natural neutralizing antibody response to the SARS-CoV-2 spike RBM in humans. <b>2020</b> ,		
71	Identification of SARS-CoV-2-specific immune alterations in acutely ill patients.		
70	Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins. <i>Scientific Reports</i> , <b>2021</b> , 11, 21601	4.9	1

69	Antibody Dynamics and Durability in Coronavirus Disease-19.. <i>Clinics in Laboratory Medicine</i> , <b>2022</b> , 42, 85-96	2.1	1
68	Corticosteroid treatment in COVID-19 modulates host inflammatory responses and transcriptional signatures of immune dysregulation. <i>Journal of Leukocyte Biology</i> , <b>2021</b> , 110, 1225-1239	6.5	1
67	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. <i>Science Advances</i> , <b>2021</b> , 7, eabj5629	14.3	8
66	Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays. <i>Microbiology Spectrum</i> , <b>2021</b> , e0088621	8.9	6
65	Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2. <i>EBioMedicine</i> , <b>2021</b> , 74, 103700	8.8	4
64	Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses.. <i>Cell Host and Microbe</i> , <b>2021</b> ,	23.4	15
63	Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern.. <i>Cell Reports</i> , <b>2021</b> , 110210	10.6	26
62	Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response.. <i>Cell Host and Microbe</i> , <b>2021</b> ,	23.4	5
61	A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection.. <i>Cell Reports</i> , <b>2022</b> , 110368	10.6	10
60	The prevalence of adaptive immunity to COVID-19 and reinfection after recovery - a comprehensive systematic review and meta-analysis.. <i>Pathogens and Global Health</i> , <b>2022</b> , 1-13	3.1	4
59	B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders.. <i>Vaccine</i> , <b>2022</b> ,	4.1	2
58	IgG3 and IgM Identified as Key to SARS-CoV-2 Neutralization in Convalescent Plasma Pools.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0262162	3.7	5
57	Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes.. <i>Viruses</i> , <b>2022</b> , 14,	6.2	2
56	Safety and immunogenicity of inactivated whole virion vaccine CoviVac against COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase I/II clinical trial.		3
55	VE607 Stabilizes SARS-CoV-2 Spike In the "RBD-up" Conformation and Inhibits Viral Entry.. <b>2022</b> ,		
54	SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses.. <i>Cell Reports</i> , <b>2022</b> , 38, 110429	10.6	6
53	SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses.		0
52	SARS-CoV-2 Spike Expression at the Surface of Infected Primary Human Airway Epithelial Cells.. <i>Viruses</i> , <b>2021</b> , 14,	6.2	3



51	SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy.. <i>MBio</i> , <b>2022</b> , e0322721	7.8	3
50	IgM responses following SARS-CoV-2 vaccination: insights into protective and pre-existing immunity.. <i>EBioMedicine</i> , <b>2022</b> , 77, 103922	8.8	1
49	Quantity of IgG response to SARS-CoV-2 spike glycoprotein predicts pulmonary recovery from COVID-19.. <i>Scientific Reports</i> , <b>2022</b> , 12, 3677	4.9	0
48	Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection.. <i>Viruses</i> , <b>2022</b> , 14,	6.2	0
47	Seroprevalence of SARS-CoV-2 antibodies among blood donors in Québec: an update from a serial cross-sectional study.. <i>Canadian Journal of Public Health</i> , <b>2022</b> , 1	3.2	0
46	CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study.. <i>BMJ Open</i> , <b>2021</b> , 11, e054208	3	2
45	ABO blood group is involved in the quality of the specific immune response anti-SARS-CoV-2.. <i>Virulence</i> , <b>2022</b> , 13, 30-45	4.7	1
44	Heterogenous Cellular and Humoral Immune Trajectories after SARS-CoV-2 Infection: Compensatory Responses in a Population-Based Cohort.		1
43	Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. <i>PLoS Medicine</i> , <b>2021</b> , 18, e1003868	11.6	2
42	Adapting Serosurveys for the SARS-CoV-2 Vaccine Era.. <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofab6321		4
41	Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen.. <b>2021</b> ,		0
40	Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses.. <i>Cell Reports</i> , <b>2021</b> , 37, 110169	10.6	2
39	Defining Antibody Seroprevalence and Duration of Humoral Responses to SARS-CoV-2 Infection and/or Vaccination in a Greek Community.. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 19,	4.6	1
38	The serological diversity of serum IgG/IgA/IgM against SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan.. <i>Health Science Reports</i> , <b>2022</b> , 5, e572	2.2	1
37	A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses.		0
36	Table_1.pdf. <b>2020</b> ,		
35	Longitudinal Analysis of Coronavirus-Neutralizing Activity in COVID-19 Patients. <i>Viruses</i> , <b>2022</b> , 14, 882	6.2	0
34	Omicron infection induces low-level, narrow-range SARS-CoV-2 neutralizing activity.		0

33	Covid-19 vaccine immunogenicity in people living with HIV-1.. <i>Vaccine</i> , <b>2022</b> ,	4.1	1
32	Humoral immune responses against SARS-CoV-2 Spike variants after mRNA vaccination in solid organ transplant recipients.		
31	VE607 Stabilizes SARS-CoV-2 Spike In the RBD-up Conformation and Inhibits Viral Entry. <i>IScience</i> , <b>2022</b> , 104528	6.1	1
30	The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice.		0
29	Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. <i>Viruses</i> , <b>2022</b> , 14, 1255	6.2	1
28	The Kinetics of SARS-CoV-2 Antibody Development Is Associated with Clearance of RNAemia. <i>MBio</i> ,	7.8	0
27	Antibodies to the Spike Protein Receptor-Binding Domain of SARS-CoV-2 at 413 Months after COVID-19. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11, 4053	5.1	0
26	High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination. <i>PLoS ONE</i> , <b>2022</b> , 17, e0272008	3.7	1
25	Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput, Serological Studies of SARS-CoV-2. <b>2022</b> , 8, 1468-1479		0
24	SARS-CoV-2 BA.4/5 Spike recognition and neutralization elicited after the third dose of mRNA vaccine.		0
23	Humoral immune responses against SARS-CoV-2 Spike variants after mRNA vaccination in solid organ transplant recipients. <b>2022</b> , 104990		1
22	COVID -19 vaccine humoral response in frequent platelet donors with plateletpheresis-associated lymphopenia.		
21	Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort. <b>2022</b> , 13,		1
20	Innate immunity and SARS-CoV-2 vaccine response in hemodialysis patients. 10.34067/KID.0002542022		0
19	A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally infected and vaccinated subjects. <b>2022</b> , 17, e0274553		0
18	Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1 $\beta$ associate with COVID-19 fatal outcome: A cross-sectional analysis. 13,		0
17	A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile.		0
16	A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses. <b>2022</b> , 111554		1

15	Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD. <b>2023</b> , 26, 105783	0
14	Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination.	0
13	SARS-CoV-2 Omicron subvariants Spike recognition and neutralization elicited after the third dose of mRNA vaccine. <b>2023</b> , 111998	2
12	Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors. <b>2023</b> , 15, 175	5
11	An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells. <b>2023</b> , 26, 105904	0
10	Kinetics of Covid-19 antibodies in terms of titre and duration among healthcare workers: A longitudinal study. 35, 201-205	0
9	Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination. <b>2023</b> , 11, 242	0
8	Assessment of the longitudinal humoral response in non-hospitalized SARS-CoV-2-positive individuals at decentralized sites: Outcomes and concordance. 13,	0
7	Cell-Free Dot Blot: an Ultra-Low-Cost and Practical Immunoassay Platform for Detection of Anti-SARS-CoV-2 Antibodies in Human and Animal Sera.	0
6	Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates. <b>2023</b> , 42, 112402	0
5	A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile. <b>2023</b> , 4, 100955	0
4	Performance Evaluation of RapiSure (EDGC) COVID-19 S1 RBD IgG/Neutralizing Ab Test for the Rapid Detection of SARS-CoV-2 Antibodies. <b>2023</b> , 13, 643	0
3	Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals. <b>2023</b> , 18, e0281689	0
2	A urine-based ELISA with recombinant non-glycosylated SARS-CoV-2 spike protein for detecting anti-SARS-CoV-2 spike antibodies. <b>2023</b> , 13,	0
1	Comparison and monitoring of antibody response in convalescent and healthy vaccinated individuals against RBD and PCS of SARS-CoV-2 spike protein. 1-8	0